Disruptive Anti-infective Technologies

Addressing multi-drug resistant infections - a global crisis.


Our therapeutic product candidates represent new, potentially game changing approaches to treating infections, including those caused by drug resistant pathogens.

Drug resistance occurs when microbes such as bacteria and viruses change in ways that allow them to grow despite antibiotic and antiviral treatment. Overuse of antibiotics has contributed to dramatic increases in the prevalence of drug resistant bacteria, such as MRSA, which require longer and more expensive courses of treatment and are associated with substantial morbidity and mortality.


Lysins are enzymes that digest the bacterial cell wall and rapidly kill bacteria. This process is much faster than conventional antibiotics, which typically require time for bacterial metabolism to occur before killing bacteria or stopping their growth. Other features which differentiate our lysins from conventional antibiotics include rapid biofilm eradication, specificity for target bacteria while preserving the healthy microbiome and a low propensity for resistance. In addition, lysins act synergistically with standard of care antibiotics, resulting in superior efficacy and reduced development of resistance to standard of care antibiotics when administered concomitantly.

Learn More
Amurin Peptides
Combating Drug Resistance

Product Pipeline

We are developing the next generation of anti-infectives.

View Full Product Pipeline »

Contrafect Corporation

We are focused on developing protein and antibody therapeutics for life-threatening infections.

Learn More »